This article describes a clinical case of a patient suffering from ulcerative colitis and cardiovascular pathology for a long time. In the clinical case, a patient with a late onset of ulcerative colitis and a sharp deterioration in cardiovascular pathology is presented. This combination of diseases is of clinical interest, because according to existing data, inflammatory bowel diseases (IBD) are predictors of increased cardiovascular risk. The clinical case describes the therapy of inflammatory bowel diseases, which can stop the symptoms of the disease and thereby reduce the risk of progression of cardiovascular pathology, describes the hypotensive, hypolipidemic therapy received by the patient. Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), affect not only the gastrointestinal tract, but also have extra-intestinal manifestations. For example, IBD develops chronic inflammation syndrome, which leads to the development of endothelial dysfunction and accelerated growth of atherosclerotic plaques. Given that inflammation triggers the early stages of atherogenesis, and an increase in inflammatory cytokines is accompanied by a higher cardiovascular risk, today there is an assumption that patients suffering from IBD have a higher risk of developing cardiovascular events than healthy ones. In our clinical case, the latest data on IBD as a risk factor for cardiovascular diseases are presented. Infl mmation plays a key role in the development of IBD and cardiovascular pathology. Understanding the main mechanisms underlying these diseases and leading to increased cardiovascular risk and worsening prognosis in patients with IBD will optimize treatment tactics and, thus, reduce the number of adverse events and mortality in this cohort of patients. The purpose of our clinical case is to attract special attention to this cohort of patients from cardiologists, gastroenterologists and therapists in order to be able to consider starting preventive prevention as early as possible.